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Abstract
Diabetes mellitus has emerged as one of the main alarms to human health in the 21st century. Pronounced
changes in the human environment, behavior and lifestyle have accompanied globalization, which resulted in
escalating rates of both obesity and diabetes, already described as diabesity. This pandemic causes deterioration of
life quality with high socio-economic costs, particularly due to premature morbidity and mortality. To avoid late
complications of type 2 diabetes and related costs, primary prevention and early treatment are therefore necessary.
In this context, effective non-pharmacological measures, such as regular physical activity, are imperative to avoid
complications, as well as polymedication, which is associated with serious side-effects and drug-to-drug
interactions.
Our previous work showed, in an animal model of obese type 2 diabetes, the Zucker Diabetic Fatty (ZDF) rat, that
regular and moderate intensity physical exercise (training) is able, per se, to attenuate insulin resistance and control
glycaemia, dyslipidaemia and blood pressure, thus reducing cardiovascular risk, by interfering with the
pathophysiological mechanisms at different levels, including oxidative stress and low-grade inflammation, which
are key features of diabesity.
This paper briefly reviews the wide pathophysiological pathways associated with Type 2 diabetes and then
discusses in detail the benefits of training therapy on glycaemic control and on cardiovascular risk profile in Type 2
diabetes, focusing particularly on antioxidant and anti-inflammatory properties. Based on the current knowledge,
including our own findings using an animal model, it is concluded that regular and moderate intensity physical
exercise (training), due to its pleiotropic effects, could replace, or at least reduce, the use of anti-diabetic drugs, as
well as of other drugs given for the control of cardiovascular risk factors in obese type 2 diabetic patients, working
as a physiological “polypill”.
Introduction
Type 2 diabetes mellitus (T2DM) achieved proportions
of a real epidemic and, according to the International
Diabetes Federation (IDF), the disease now affects 246
million people worldwide and is expected to affect
about 380 million by 2025 [1]. This panorama is even
more dramatic if considered that over the past 20 years
its prevalence has increased dramatically among children
and adolescents. As such, the incidence/prevalence of
serious diabetic complications (which includes cardio-
vascular disease, kidney failure, blindness and amputa-
tions) as well as the premature death, will unequivocally
deteriorate life quality and exacerbate health costs,
unless more effective primary and secondary pharmaco-
logical and non-pharmacological (lifestyle interventional)
strategies become more widely available and implemen-
ted. The therapeutic arsenal now available to manage
T2DM has proved inefficacy to prevent the rise in inci-
dence of cardiovascular events, the leading cause of
morbidity and early mortality of diabetic patients. The
improvement of cardiovascular profile will depend not
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only on the reduction of glycosylated hemoglobin
(HbA1c) levels, but also of other factors, such as blood
pressure. The Steno-2 study [2] clearly demonstrated
that only intensive multifactorial intervention, involving
pharmacological measures and lifestyle modifications,
could promotes sustained beneficial effects on rates of
death and cardiovascular disorders in T2DM patients.
Several prospective studies have associated time spent
in sedentary activities, such as TV watching and compu-
ter or video-games use, with increasing obesity [3] and
T2DM development [4]. Thus, the low level of physical
activity (sedentarism) has been considered a risk factor
for early mortality, in parallel with smoking habits,
arterial hypertension and dyslipidaemia. The regular
practice of moderate intensity physical exercise (train-
ing) showed capacity to reduce body weight, improve
insulin sensitivity, increase circulating levels of high-
density lipoprotein (HDL), decrease triglyceride levels
and normalize blood pressure [5,6].
This paper will review the effects of regular practice of
an aerobic exercise program of moderate intensity
(training) in the prevention of T2DM or attenuation of
its progression, based on the present literature as well as
on our knowledge using an experimental model of obese
T2DM. We will firstly focus on the effects at different
risk factors related to insulin resistance (IR) and glucose
intolerance stages, which precedes the onset of sustained
T2DM; thereafter, the review will focused on the effects
promoted by exercise training on oxidative stress and
low-grade inflammation, which play a key role on the
onset and progression of diabetes.
Natural history of T2DM: role of oxidative stress
and inflammation
T2DM is a complex heterogeneous group of metabolic
conditions characterized by increased levels of blood
glucose due to impaired insulin action and/or secretion
[7]. Physiologically, the pancreatic b-cells constantly
synthesize insulin, regardless of blood glucose levels.
Insulin is stored within vacuoles and released once trig-
gered by an elevation of the blood glucose level. Insulin
is the key hormone concerning the regulation of glucose
uptake from blood into most cells, including skeletal
muscle cells and adipocytes. Insulin is also the major
signal for conversion of glucose to glycogen for internal
storage in liver and skeletal muscle cells. A drop in the
blood glucose level results in decrease of insulin release
from b-cells and in increase of glucagon release from
a-cells, which stimulates glycogen to glucose conversion.
Following an overnight fast, glucose is largely produced
by glycogenolysis and gluconeogenesis.
There are three key defects in the onset of hyperglyce-
mia in T2DM: increased hepatic glucose production,
diminished insulin secretion and impaired insulin action
[8]. Insulin resistance refers to a suppressed or delayed
response to insulin and is generally a post-receptor phe-
nomenon, due to a defect in cells that respond to insu-
lin, rather than on insulin production.
Insulin resistance in muscle and liver, together with b-
cell failure, are pivotal pathophysiologic defects in
T2DM. It is now recognized that b-cell failure occurs
much earlier and is more severe than previously
thought. Subjects in the upper tertile of impaired glu-
cose tolerance (IGT) are maximally or near-maximally
insulin resistant and have lost over 80% of their b-cell
function. In addition to muscle, liver and b-cells, the fat
cell (accelerated lipolysis), the gastrointestinal tract
(incretin deficiency/resistance), the a-cell (hyperglucago-
nemia), the kidney (increased glucose reabsorption) and
the brain (insulin resistance) all play important roles in
the development of glucose intolerance in type 2 dia-
betic individuals.
The insulin resistance observed in obese T2DM
patients is secondary to changes in insulin receptors sig-
nal transduction, arising from genetic and/or environ-
mental factors, such as excessive caloric consumption,
sedentary lifestyle and obesity [9]. T2DM emerges when
these change are associated with a progressive decrease
in the secretory capacity of pancreatic beta cells (relative
insulinopenia). It is a silent disease, in which the loss of
secretory capacity begins years before the clinical diag-
nosis. In the phase of insulin resistance, glucose intoler-
ance or glycaemia rise may occur in the unfed state. As
long as the b-cells are able to augment insulin secretion
to compensate insulin resistance, glucose tolerance
remains normal. However, with time, the b-cells begin
to fail and the postprandial plasma glucose levels (initi-
ally) and the fasting plasma glucose concentration (sub-
sequently) begin to rise, leading to the onset of overt
diabetes [9,10].
It has been suggested that chronic hyperglycaemia or
even the intermittent blood glucose elevations observed
in patients with apparent acceptable glycaemic control
may contribute to the development of macro and/or
microvascular complications [11,12]. However, many
different pathophysiological pathways may be simulta-
neously activated, which includes oxidative stress and
low-grade inflammation.
Role of oxidative stress in the progression of T2DM
It has been shown that reactive oxygen species (ROS)
are produced in various tissues under diabetic condi-
tions, by the several mechanisms, such as non-enzymatic
glycosylation reactions, electron transport chain in the
mitochondria and membrane-bound nicotinamide ade-
nine dinucleotide phosphate (NADPH) oxidase [13].
Several lines of evidence support a close association
between oxidative stress and diabetes evolution,
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revealing that oxidative stress secondary to hypergly-
caemia and hyperlipidaemia occurs before the appear-
ance of clinical manifestations of late diabetes
complications, suggesting a key role in the pathogen-
esis of the disease. Therefore, insulin resistance and
pancreatic b-cell dysfunction, which are hallmarks of
type 2 diabetes, are modulated by ROS [14-16]. Under
diabetic condition, chronic hyperglycaemia may induce
large amounts of ROS that are responsible for the pro-
gressive dysfunction of b cells, worsening insulin resis-
tance and further promoting relative insulin deficiency
ROS [17]. It was previously reported that ROS disrupt
insulin-induced cellular redistribution of insulin recep-
tor substrate-1 (IRS-1) and phosphatidylinositol 3-
kinase (PI3K), thus impairing insulin-induced glucose
transporter type 4 (GLUT4) translocation in 3T3-L1
adipocytes [14]. The increase of intracellular free fatty
acids (FFA), in turn, leads to a decreased translocation
of the glucose transporter subtype 4 (GLUT4) to the
plasma membrane, leading to insulin resistance in
muscle and adipose tissue [18]. In this context, insulin
resistance may be considered a compensatory mechan-
ism that protects the cells against further insulin-
stimulated glucose and fatty acid uptake and, therefore,
oxidative damage. Many studies have previously sug-
gested that ß-cell dysfunction results from prolonged
exposure to high glucose and FFA levels, or a combi-
nation of both [14,15]. Beta cells, in particular, are
particularly sensitive to ROS because they are low in
free-radical quenching (antioxidant) enzymes such as
catalase, glutathione peroxidase, and superoxide dis-
mutase [19,20]. The ROS formed will also indirectly
damage cells by activating a variety of stress-sensitive
intracellular signaling pathways, including Nuclear fac-
tor-kB (NF-kB), mitogen-activated protein kinase p38
(p38MAPK), kinases JunNH2- terminal/kinases of pro-
teins activated by stress (JNK/SAPK), hexosamines,
protein kinase C (PKC) and polyol pathway [15,21,22].
The activation of these cellular signaling cascades is
linked not only with the development of diabetic com-
plications but also with the insulin resistance and pan-
creatic b cell dysfunction. Among the signaling
cascades, the NF-kB pathway plays a central role as
intermediary of immune and inflammatory responses.
This nuclear factor is responsible for regulating the
expression of a large number of genes, including those
related to diabetes complications, such as the vascular
endothelial growth factor (VEGF) [20]. Being an intra-
cellular signaling pathway target of hyperglycaemia and
ROS, its activation may also be induced by endogenous
and exogenous stimuli, in addition to those above
mentioned, such as excess of FFA, tumour necrosis
factor a (TNF-a), interleukin 1b (IL-1b) and other
pro-inflammatory cytokines, advanced glycation
endproducts (AGE) related to receptor for AGE
(RAGE), p38MAPK, DNA damage, viral infection and
ultraviolet radiation [21].
Role of inflammation in the progression of T2DM
Obesity, as a result of inactivity in combination with
overeating, plays a key role in the development of pan-
creatic beta-cell dysfunction and in insulin resistance.
An increased mass of stored triglycerides (TGs), espe-
cially in visceral or deep subcutaneous adipose stores,
leads to large adipocytes, that are resistant to insulin-
evoked lipolysis suppression, resulting in increased
release of FFA and glycerol. This “dyslipidaemic pheno-
type of diabetes”, characterized by increased content of
TGs and oxidized low density lipoproteins (ox-LDL),
together with decreased levels of HDL, is responsible for
the lipotoxicity profile of diabetes. Lipotoxicity has been
used to describe the deleterious effect of tissue fat accu-
mulation on glucose metabolism and includes the
notion that increased plasma FFA/intramyocellular
levels of toxic lipid metabolites (such as long-chain fatty
acyl CoAs, diacylglycerol and ceramides) play a role in
the pathogenesis of muscle/liver insulin resistance.
In addition, fat cells produce adipocytokines, which
go through distant sites (such as muscle, liver and
arterial tissue), where exert deleterious effects on
metabolism and vascular function. Adipose tissue of
obese and type 2 diabetic individuals is infiltrated by
mononuclear cells and is in a state of chronic inflam-
mation [23]. The adipocytes and infiltrated macro-
phages secrete pro-inflammatory/pro-thrombotic
cytokines, such as the TNF-a, interleukin-6 (IL-6),
resistin, adipsin, acylation-stimulating protein (ASP),
plasminogen activator inhibitor 1 (PAI-1) and angio-
tensinogen, that promote atherogenesis and cause
insulin resistance. Adipocytes also produce adiponec-
tin, a potent insulin-sensitizing and anti-atherogenic
cytokine, now included in a vast group of substances
named adipokines or adipocytokines. Low adiponectin
levels have been correlated with visceral obesity and
whole-body insulin sensitivity [24]. This fat cell hor-
mone acts as an insulin sensitizer, inhibiting TGs for-
mation in liver and stimulating fatty acid oxidation in
muscle in an 5’ adenosine monophosphate-activated
protein kinase (AMPK) and peroxisome proliferators
activated receptor alpha (PPAR-a)-dependent manner
[25]. Despite their apparent importance in the insulin
resistance syndrome, aforementioned adipokines are
just examples of a family of adipocyte-derived factors
that modulate insulin resistance and systemic inflam-
mation. Besides new adipokines, also certain myokines
now appear to affect insulin sensitivity and inflamma-
tory responses. As such, the list of insulin (de)sensitiz-
ing proteins and cytokines is still far from complete.
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The secretion of citokines depends not only on the
amount of adipose tissue but also of its location, being
visceral or intra-abdominal fat more harmful than sub-
cutaneous fat. The pro-inflammatory effects of cyto-
kines are felt at the intracellular levels of signaling
cascades and involves the pathways of NF-B and
JNKs [26,27].
The increase of pro-inflammatory cytokines, associated
with the dyslipidaemic profile in T2DM, may not only
modulate the function of pancreatic beta cells but also
their survival. Several studies showed that exposure of
b cells to high levels of saturated fatty acids and lipopro-
teins undertake to their death, and this effect is acceler-
ated by hyperglycaemia, demonstrating that lipotoxicity
and glucotoxicity, in concert, determinate beta-cell fail-
ure [28-31].
The briefly preceding review of the key pathophysiolo-
gical mechanisms of T2DM highlights several relevant
aspects for the therapeutics. First, effective treatment of
T2DM will require combination of multiple drugs to
correct the various pathophysiological defects. Second,
treatment should not be simply directed to HbA1c
reduction, but also based upon known pathogenic
abnormalities, which includes the preservation of antiox-
idant and anti-inflammatory capacity. Third, since pro-
gressive b-cell failure is to be prevented, therapy must
be started early in the natural history of type 2 diabetes.
Exercise training as a therapeutic modality in
T2DM
Physical inactivity has been identified as a stronger pre-
dictor of chronic diseases even when compared with
traditional risk factors, such as hypertension, hyperlipi-
daemia, diabetes and obesity. Moreover, regular physical
activity appears to protect against premature death,
independently of obesity.
Several studies, clinical and experimental, have been
assessing the role of regular physical activity (training)
on cardiovascular and cardiometabolic disorders, includ-
ing on diabetes. Although results from studies using ani-
mals cannot be directly extrapolated for humans, animal
models of T2DM could offer excellent opportunities to
evaluate experimental conditions and to assess tissues
that cannot be tested in humans, thus improving the
knowledge about the endocrine, metabolic and morpho-
logical changes underlying the pathogenic mechanisms
of the disease and the treatment options.
In the following topics we will review the benefits of a
particular physical exercise (training) in the wide patho-
physiological aspects associated with T2DM, focusing on
antioxidant and anti-inflammatory properties, based on
the information already available in the literature, from
both clinical and experimental studies, and in particular
on the data obtained from our own experiments using
an animal model of obese T2DM, the Zucker Diabetic
Fatty (ZDF fa/fa) rats.
In order to not repeat the information alongside the
text, the physical exercise program performed by us,
which will be mentioned during the review, was a regu-
lar and moderate intensity aerobic exercise (defined as
training), consisting of 12 weeks (1 h/day, 3 times/week)
of swimming program, voluntary, for both the male
obese diabetic rats (ZDF fa/fa) and the male control
lean animals (ZDF +/+), between 8 and 20 weeks of age
[32-34]. In brief, the protocol used was: the animals,
maintained under controlled temperature (22°C), humid-
ity (60%) and lighting (12 h of light) conditions, given a
rodent maintenance chow (A-04 Panlab, Barcelona,
Spain) adjusted to their respective weights (100 mg/g of
weight) and distilled water ad libitum, perform their
exercise in a cylindrical tank, 120 cm in diameter and
80 cm in height, containing water with a controlled
temperature (30 -32°C); the animals were placed in the
tank every day at the same hour (09.00 -10.00 h) under
the supervision of the same person; the swimming per-
iod was initially for 15 min/d and was gradually
increased such that the rats were able to perform exer-
cise for 60 min/d, which was achieved in 1 wk; after
1 wk of this training period, the rats were made to swim
for 1 h, three times a week; at the end of each exercise
session, the animals were dried and kept in a warm
environment; the sedentary rats were kept in the con-
tainer where the swimming sessions were held for a per-
iod of 60 min to ensure that these control rats
underwent the same amount of stress as the test animals
that performed exercise. The animals that practiced
exercise were sacrificed 48 h after the end of the last
training session to minimize the acute effects of the
exercise. The night before sacrifice, food was removed
from the animal cages.
Physical activity, obesity and body fat distribution
Our studies showed that exercised diabetic rats pre-
sented, when sacrificed 48 h after the last bout training
session, a trend to increase body weight, which might be
due to an increase in muscle mass [34]. Despite the lack
of measurement of the animal body fat amount, a
reduction in total visceral or subcutaneous fat in exer-
cised animals cannot be excluded. Similar effect was
observed by other studies in humans, confirming that
after the training there was an increase in muscle mass
with decrease in fat mass [35,36].
In the same work, Teixeira de Lemos et al. [34]
showed that the weight of some organs or tissues (heart,
liver, kidneys and muscle) were heavier in the exercised
diabetic rats when compared with the sedentary animals,
thus confirming that training leads to important mor-
phological and physiological adaptations to maintain
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body homeostasis, as previously suggested by others
[37,38]. In addition, the results suggest that the mainte-
nance in time of training is an important factor for the
appearance of those adaptations.
The study conducted by Tuomilehto et al. (2001) pro-
vided evidence that T2DM, in both women and man at
high cardiovascular risk, can be prevented by lifestyles
modifications, with a decrease of overall incidence of
diabetes of 58% [39]. Regarding physical exercise prac-
tice, which has included components designed to
improve both cardiorespiratory fitness and muscle
strength, the results showed that more than 4 h/week of
exercise was associated with a significant reduction in
risk of diabetes even without weight loss [39]. Some of
the key beneficial effects of an exercise program include
visceral obesity reduction and muscle mass increase.
Randomized control trials conducted in individuals with
normal body mass index (BMI), as well as in patients
with abdominal obesity and T2DM, demonstrated that
physical exercise regularly practiced contributes to
diminish total, visceral and subcutaneous fat, even with-
out weight loss, together with improvement of glycaemia
and with increase of FFA oxidation and, thus, to an
amelioration of the diabetes [40-42].
Physical exercise and glycaemia and insulinaemia control
The first aim of T2DM treatment is hyperglycaemia
control, as a way of reducing chronic diabetic compli-
cations, namely of cardiovascular nature. The Ameri-
can Diabetes Association (ADA) recommends a value
of HbA1c above 7%. Our group demonstrated, using
the training protocol above described in ZDF (fa/fa)
rats, that hyperglycaemia was prevented by exercise,
together with a significantly lower value of HbA1c
(-6,6%), when compared to sedentary counterpart, rein-
forcing the idea of a effect maintained over time
[33,34]. This results were corroborated by Kyraly et al.
(2008) in ZDF rats submitted to forced swim training
(1 h/day; 5 days/week during 13 weeks) [43]. Addition-
ally, in our study the hiperinsulinaemia was partially,
but significantly, corrected in the trained rats, which
was accompanied by reduction of insulin resistance,
given by the lower HOMA (homeostasis model assess-
ment), and index of insulin resistance. Thu, we
hypothesize that swimming training was able to
improve peripheral insulin resistance, although the less
action on hepatic resistance, suggesting that hyperinsu-
linaemia could be a reflex of insulin resistance in the
liver, not improved by exercise [33,34].
Concerning studies in humans, in a meta-analysis
which reviewed the studies concerning exercise inter-
vention of at least 8 weeks in type 2 diabetic individuals,
regular aerobic exercise showed a statistically and clini-
cally significant effect on HbA1c, suggesting that this
non-pharmacological intervention improve glycaemic
control, while having little effect on body weight [44].
Similar results were encountered in another meta-analy-
sis on the effect of exercise practice, which included 14
studies (12 with aerobic exercise and 2 with resistance
exercise) [45], demonstrating that the effect of exercise
on HbA1c (the major marker of glycemic control), is a
well established finding.
The amelioration on glucose metabolism by exercise
training may occur primarily through three distinct
mechanisms: i) stimulation of glucose transport to mus-
cle; ii) increased in insulin action on cells of the organs
involved in the exercise; iii) positive regulation of signal-
ing pathway stimulated by insulin as a result of regular
exercise.
Exercise has been indicated as an “insulin-like” activity
because of the increase of muscle’s capacity to capture
circulating glucose, due to decreased intramuscular fat
reserves [40]. Christ-Roberts et al. (2004) found that
exercise training significantly increased expression of
GLUT4 glucose transporter in overweight nondiabetic
and diabetic subjects, by 38% and 22%, respectively
[46,47]. Akt protein expression, which was decreased by
about 29% in the diabetic subjects before training, when
compared to the nondiabetics, increased significantly in
both groups [46]. Furthermore, it was also observed that
in skeletal muscle exercise training affects the transcrip-
tional regulation of the gene of the IRS-1 and the post-
transcriptional regulation of the PI3-kinase expression
[48,49]. The increased capacity of the muscle to oxidize
fat in response to aerobic exercise is also a major
mechanism by which exercise training improves insulin
sensitivity in the muscle [50]. Taken together, the above
mentioned actions of exercise (training) on skeletal mus-
cle contribute to regulate blood glucose levels.
Exercise and dyslipidaemia
Chronic exercise (training) has favorable effects on lipid
profile [34,51], being nowadays viewed as one of the
best non-pharmacological strategies for the prevention
or attenuation of diabetic dyslipidaemia. Our group
demonstrated that aerobic exercise training improved
dyslipidaemia in ZDF rats, namely by reducing the total-
cholesterol (T-Chol) and triglycerides (TGs) [34].
Among other benefits, exercise stimulates lipolytic activ-
ity (with decreased plasma TG), promotes the use of
FFA as an energy source and increases HDL concentra-
tion. Furthermore, favorable changes in the quantity and
composition of LDL particles were also shown, as well
as on the quality of HDL [52,53]. The primary mediator
mechanism of these changes seems to be the beneficial
influence of regular exercise on the activity of peripheral
enzymes, such as lipoprotein lipase (LPL), lecithin-cho-
lesterol acyltransferase (LCAT) and hepatic lipase (HL)
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[51]. In addition to the regulation of the mechanism of
hepatic lipid transformation, moderate physical exercise
increases the oxidative capacity of several tissues,
including the skeletal muscle, which is under low oxida-
tive capacity in situations of insulin resistance. Physical
exercise increases the number of capillaries and oxida-
tive fibers in muscle, increasing lipolysis, which allows
free flow of fatty acid to the tissue, reducing its concen-
tration in plasma, which is an indicator of its uptake
and oxidation by tissues [54].
It seems clear now that regular exercise training is
able to improve lipid metabolism. But is this evident in
human studies? Type 2 diabetes populations have been
shown to improve fasting blood lipid profile following
long-term exercise interventions, with or without dietary
restriction [55,56]. Furthermore, exercise practice in
Type 2 diabetes patients showed improved glycemic
control, body composition, blood pressure, muscle
strength, and workload capacity, together with attenu-
ated progressive increase in exogenous insulin require-
ments [57]. In accordance with earlier reports, the
randomized trial conducted by Sigal et al. (2007) showed
that, despite an unaltered body weight, combined endur-
ance and resistance type of exercise training is able to
induce regional changes in fat and lean muscle mass in
obese T2DM patients [58]. Furthermore, Lira et al.
(2007) also reported that low and moderate exercise
intensities (training) appear to promote clear benefits on
lipid profile [59].
The exercise is also able to activate an alternative
pathway: the AMPK [60]. This enzyme acts on the liver,
muscle and adipocytes by increasing fatty acid oxidation,
decreasing cholesterol synthesis, lipogenesis and lipoly-
sis, and even modulating insulin secretion on pancreatic
islets [61]. Apart from the effect that AMPK appears to
have on lipid oxidation, it also plays an important role
in decreasing the glucose levels, being able to stimulate
GLUT-4 increment [62].
Considering the data above mentioned, it seems
obvious that the regular practice of an exercise program
has a positive effect on the dyslipidaemic profile dis-
played by patients with T2DM whic could not be
neglected.
Physical exercise and blood pressure
It is widely accepted that the exercise practiced on a
regular basis has an antihypertensive effect in humans
[63,64]. Indeed, regular exercise (training) is able to
reduce heart rate, improving the sensitivity of aortic bar-
oreceptors, which contributes to a more efficient regula-
tion of blood pressure [65]. The beneficial effects on
hypertension (blood pressure lowering, either systolic or
diastolic) due to decreased activity of both the sympa-
thetic nervous system and the renin-angiotensin system
was also documented. Other mechanisms responsible
for the antihypertensive effect of training include the
decrease in peripheral arterial resistance caused by vaso-
dilatation [66]. Besides improving glycaemic control, a
meta-analysis showed that structured exercise interven-
tion studies in non-insulin-dependent Type 2 diabetes
patients reduce systolic blood pressure of about -4.16
mmHg [67]. Such reduction in mean blood pressure are
clinically relevant and similar to the effects produced by
combined therapy of an angiotensin-converting enzyme
(ACE) inhibitor and an thiazide diuretic [68].
Also in animals, as shown by our studies using the
ZDF rats as model of type 2 diabetes, training (swim-
ming) has promoted a decrease in systolic and mean
blood pressure and in heart rate, together with a dimin-
ishment of differential pressure [33,34], suggesting an
improvement of vascular arterial compliance, with
reduction in cardiac work and a left ventricular hyper-
trophy amelioration. The increased arterial stiffness
appears to be one of the factors that best combine car-
diovascular risk and atherosclerosis. Differential pressure
has been indicated as an indirect measure of arterial
stiffness and a better predictor of coronary risk. By pre-
venting the increasing of differential pressure regular
exercise training positively influence the cardiovascular
diabetic complications, such as diabetic ischemic heart
disease, which is often asymptomatic.
Exercise (training), oxidative stress and T2DM
Exercise and oxidative stress - pathophysiological aspects
Exercise is associated with increased formation of free
radicals, mainly due to increased O2 consumption by
active tissues. Several studies have shown that the
amount of free radicals in biological tissues is increased
after acute and/or chronic exercise, which coincides
with the presence of tissue damage [69]. Most of the O2
consumed is used in the mitochondria for oxidative
phosphorylation, where it is reduced to water. However,
a small but significant fraction of O2 consumed may
leave the electron transport chain to produce ROS; it is
estimated that approximately 2-5% of oxygen used by
mitochondria are converted into free radicals [70].
Chronic exercise of moderate intensity (training) posi-
tively alters the oxidative homeostasis of cells and tis-
sues, by decreasing the basal levels of oxidative damage
and increasing resistance to oxidative stress [71]. In fact,
regular exercise causes adaptations in the antioxidant
capacity, protecting cells against the harmful effects of
oxidative stress, thus preventing cellular damage [72,73].
Adaptation to oxidative stress in trained individuals is
clearly evidenced by a decrease in DNA damage, by sus-
tained levels of protein oxidation and by an increment
of resistance against chronic administration of hydrogen
peroxide [74]. Training is also able to alter the
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metabolism of purines, reducing the availability of sub-
strate for xanthine oxidase (XO) in the trained muscle
and plasma content of hypoxanthine and uric acid.
Exercise and oxidative stress in T2DM
Oxidative stress has often been implicated in the patho-
genesis of micro and macrovascular diseases observed in
diabetic individuals. Some data support a role of regular
exercise in reducing lipid peroxidation. Indeed, if regular
exercise can show a protective effect against oxidative
stress in individuals with diabetes mellitus, their use, as
a non-pharmacological therapeutic measure for T2DM,
become even more attractive
The cardiovascular adaptations observed by practicing
regular physical exercise (training) include, as above
mentioned, not only lowering blood pressure, but also
aggregation and adhesiveness of platelets and increment
of cardiac blood flow [75,76]. These adaptations may be
mediated, at least in part, by a hyper-regulation of basal
nitric oxide (NO) production. Consistent with this idea
are the reports of increased NO production in subjects
who practiced chronic exercise, coincident with decrease
in blood pressure and platelet activation [77]. The aug-
ment of NO production observed during acute exercise
is able to induce protective adaptations by interaction
with various transcription factors and, thereby, influence
gene expression of antioxidant enzymes [78].
Although antioxidant properties have been attributed
to acid uric, high level of uric acid is strongly associated,
and in many cases predicts, development of hyperten-
sion, visceral obesity, insulin resistance, dyslipidaemia,
T2DM, kidney disease, and cardiovascular events
[79,80]. Several studies suggest that, under certain con-
centrations, uric acid might have antioxidant activity,
preventing lipid peroxidation; nevertheless, its associa-
tion with chronic disease highlights the uric acid oxi-
dant-antioxidant paradox [81]. Ideally, exercise training
should be able to reduce pro-inflammatory levels of uric
acid to anti-oxidant and protective levels. Considering
the negative consequences associated with oxidative
stress, our group demonstrates in diabetic ZDF animals
submitted to a swimming training protocol an increased
antioxidant enzyme activity, with concomitant decline in
oxidative aggression [34]. This effect of training might
suggests a beneficial regulation of XO activity, which
might be viewed as a possible therapeutic strategy for
treatment diabetes-associated diseases [80].
In our animal studies, using the ZDF rat, the exercise-
induced oxidative injury decrease was accompanied by
an augmentation in serum total antioxidant status
(TAS) and in superoxide dismutase (SOD) activity
(Figure 1), reinforcing the antioxidant action of training.
Furthermore, the decline observed in 3-nitrotyrosine
(3-NT) serum levels of trained diabetic rats suggests a
decrease in peroxynitrite contents, corroborating the
work of Fukai et al. (2000), which demonstrated that
training promotes the increase of endothelial nitric
oxide syntase (eNOS) gene expression and its phosphor-
ylation, thus protecting endothelial cells [82].
Exercise (training), inflammation and T2DM
Exercise and inflammation - pathophysiological aspects
According to Kasapis et al. (2005), a single session of
exercise triggers an increase in pro-inflammatory cyto-
kines release, associated with leukocytosis and increased
plasma concentration of C-reactive protein (CRP) [83].
This pro-inflammatory response to acute exercise is
accompanied by a sudden increase in oxidative stress
and, followed by adaptive mechanisms against inflam-
mation [84]. Moreover, longitudinal studies showed that
regular training induces a reduction in CRP levels, sug-
gesting an inflammatory action, viewed in several condi-
tions, such as T2DM, insulin resistance and other
cardiovascular/cardiometabolic diseases [84]. Regular
exercise is associated with a decrease of CRP, IL-6 and
TNF-a levels and, simultaneously, with increase of anti-
inflammatory substances, such as IL-4 and IL-10 [84],
reinforcing the anti-inflammatory nature of exercise
[85,86].
Cytokines are released not only from mononuclear
cells but also from muscle cells. Starkie et al. (2003)
showed that physical exercise directly inhibits endo-
toxin-induced TNF-a production in humans, most likely
through IL-6 release from exercising muscle [87]. Typi-
cally, IL-6 is the first cytokine present in circulation
after exercise practice, followed by an increase in IL-1ra
and IL-10 [88]. The ubiquitous role of IL-6 and the
hypothesis of an exercise-induced anti-inflammatory IL-
6 release was recently reviewed [89,90]. Therefore, IL-6,
a multifactorial cytokine, regulates cellular and humoral
responses and plays a pivotal role in inflammation,
being associated with several pathological conditions,
including type 2 diabetes, emerging as an independent
early predictor for T2DM and as a marker of low-grade
inflammation [89,90]. However, what is even more inter-
esting concerning IL-6, as Fisman and Tenenbaum
(2010) recently commented, is the putative beneficial
effects played as an anti-inflammatory factor, which is
particularly evident in insulin sensitivity during exercise
[89]. Therefore, a marked increase in circulating levels
of IL-6 after exercise without muscle damage has been a
remarkably consistent finding. The magnitude by which
plasma IL-6 increases is related to exercise duration,
intensity of effort, muscle mass involved in the mechani-
cal work and endurance capacity [91]. The release by
muscle of a humoral factor into the circulation after
exercise improves insulin sensitivity, most probably
through AMPK [89]. IL-6 has been indicated as the
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strongest candidate for the humoral factor released after
exercise, working in a hormone-like fashion, in which it
is released by the muscle, now viewed as an endocrine
organ, for influencing other organs [89]. Although this
hypothesis deserve further clarification, the role of IL-6
as both the “good” and the “bad”, depending on the cir-
cumstances, as commented by Fisman and Tenenbaum
(2010), opens new windows on the way interleukins act,
and in particular concerning the effects of exercise in
insulin resistance and diabetes. In this anti-inflammatory
environment, IL-6 inhibits TNF-a production, which
was confirmed by studies in animals [92]. Furthermore,
exercise also suppresses secretion of TNF-a by pathways
independent of IL-6, as shown by the results obtained
with knockout mice for IL-6 submitted to exercise [93].
The anti-inflammatory nature of regular exercise (train-
ing) has been associated to a reduced cardiovascular dis-
ease, particularly due the training-evoked increased
expression of antioxidant and anti-inflammatory media-
tors in the vascular wall, which could directly inhibit
atherosclerosis development [94].
The information now available concerning the effects
of physical exercise on adiponectin levels is scarce and
divergent [95]. There were several studies that showed
that chronic exercise (programs of 6 weeks to 6 months)
did not induced changes in adiponectin levels [96]. Kri-
ketos et al. (2004) also reported, after 2-3 sessions of
moderate exercise, a remarkable increase in adiponectin
levels (260%), that remaining elevated for 10 weeks,
without body weight modifications [97]. The systematic
review performed by Simpson and Singh (2008), consid-
ering literature searches databases conducted from ten
years and including 8 randomized controlled trials, con-
cluded that exercise of varying prescription increase
serum adiponectin in 38% of de trials, demonstrating
small-to-moderate effect sizes [95]. Nevertheless, the
same study showed inconsistent data in the literature
for increasing adiponectin levels after short-term expo-
sure to robust aerobic or resistance training of moder-
ate-to-high intensities, reinforcing the need of more
studies reporting consistent findings concerning a clear
relationship between changes in adiponectin contents
and exercise mode, intensity and frequency [95].
Exercise and inflammation in T2DM
The above data highlighted the idea that beneficial effect
of exercise seem to be related to its ability to decrease
inflammatory cytokines levels and/or increase anti-
inflammatory ones, which might be also true for patho-
logical conditions, such as type 2 diabetes.
The results from the studies of Teixeira de Lemos et
al., above mentioned [33,34], clearly demonstrated the
anti-inflammatory capacity of swimming exercise train-
ing in the ZDF rat, a model of obese T2DM. Actually,
training was able to prevent the increase of pro-inflam-
matory cytokines and CRP observed in the diabetic rats.
Those findings were in the line of those of Martin-Cor-
dero et al. (2009), which found that obese Zucker rats, a
model of metabolic syndrome, presents impairment of
pro-inflammatory cytokines (TNF-a, IL-6, IL-1beta and
Figure 1 Evolution of serum MDA (A), TAS (B) and blood SOD (C) levels between T0 and Tf in control (+/+) and diabetic (fa/fa) Zucker
diabetic fatty rats: control sedentary (black circles), control exercised (white circles), diabetic sedentary (black diamonds) and diabetic
exercised (white diamonds) . Data are means ± sem of eight separate values (rats) per group. Statistical significance: aaa P < 0.05: sedentary
diabetic vs sedentary control; bP < 0.05 and bbbP < 0.001: exercised control or diabetic vs sedentary control or diabetic, respectively. MDA,
malondialdehyde; SOD, superoxide dismutase; TAS, total antioxidant status. Adapted from [32].
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interferon gamma: IFN-g) release by macrophages, an
effect that was improved by habitual physical activity
[98,99]. Furthermore, Teixeira de Lemos et al. also
found an increment of serum adiponectin in trained
obese diabetic ZDF (fa/fa) rats to levels nearby those
found in the control lean rats (Figure 2). Adiponectin
anti-inflammatory actions has been associated with
improvement of cardiometabolic profile, which might be
due, at least in part, by regulatory actions on other fac-
tors, including on TNF-a, IL-6 and CRP levels [100],
which was also demonstrated in our study using the
ZDF rat submitted to swimming regular exercise train-
ing [33,34] (Figure 2). Considering that adiponectin
measure was performed 48 hours after the last training
session, the results may suggest an extension of the
anti-inflammatory effect obtained by a single bout of
exercise.
Pancreatic islets from type 2 diabetic patients present
amyloid deposits, fibrosis and increased cell death,
which are associated with the inflammatory response
[101]. T2DM is also characterized by hyperglycemia,
dyslipidaemia, increased circulating inflammatory factors
and cellular stress, which are critical in precipitating
islet inflammation in vivo. Chronic exposure of b cell to
these mediators induces excessive production of ROS
and activation of caspases, which inhibit insulin secre-
tion and promote apoptosis of pancreatic b cells [102].
The impact of islet-derived inflammatory factors and
islet inflammation on b-cell function and mass may be
both beneficial and/or deleterious. Depending on their
roles in regulating pancreatic b-cell function, some cyto-
kines are protective while others can be detrimental.
Actually, chronic exposure of islets to IL-1b, IFN-g,
TNF-a and resistin inhibits insulin secretion and
Figure 2 Evolution of serum adiponectin (A), C-reactive protein (B), IL-6 (C) and TNF-a (D) levels between T0 and Tf in control (+/+)
and diabetic (fa/fa) Zucker diabetic fatty rats: control sedentary (black circles), control exercised (white circles), diabetic sedentary
(black diamonds) and diabetic exercised (white diamonds). Data are means ± sem of eight separate values (rats) per group. Statistical
significance: a fa/fa versus +/+; b Tf versus T0; c exercised rats versus sedentary rats; *P < 0.05, **P < 0.01 and ***P < 0.001. IL-6, interleukin 6; T0,
initial time; Tf, final time; TNF-a, tumor necrosis factor-a. Adapted from [[33] and [[34]].
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induces b cells apoptosis. Other cytokines, such as adi-
ponectin and visfatin, exert protective effects on pan-
creatic b cell function. In addition to circulating
cytokines, islets also produce a variety of cytokines in
response to physiologic and pathologic stimuli, and
these locally produced cytokines play important roles in
regulation of pancreatic b-cell function as well [103]. To
maintain the normal pancreatic b-cell function, the dele-
terious and protective cytokines need to be balanced.
The abnormal control of cytokine profile in islets and in
plasma is associated with pancreatic b-cell dysfunction
and type 2 diabetes [103]. All those emerging evidences
reinforce the paradigm that islet inflammation is
involved in the regulation of b-cell function and survival
in T2DM.
Few studies have previously reported the putative ben-
eficial effects of regular exercise practice (training) on
pancreas, per se. Studies in Otsuka Long Evans Tokush-
ima Fatty (OLETF), Goto-Kakizaki (GK), Zucker fatty
(ZF) and ZDF rats have shown improvements in whole-
body insulin sensitivity and preservation of b-cell mass
with exercise training [104,105]. Insulin sensitivity
improvements by exercise may confer an indirect benefi-
cial effect on b-cells by decreasing insulin demand and
minimizing b-cell exhaustion, at the same time minimiz-
ing hyperglycemia mediated loss in b-cell function [106],
but a direct effect on pancreatic function could not be
excluded. Although almost all the studies have demon-
strated b-cell mass preservation with exercise training,
none of them focus on inflammation. The recognition
that islet inflammation is a key factor in TD2M patho-
genesis has highlighted the concern regarding the pro-
tection of pancreatic islets and endocrine function.
Thus, restoring the normal cytokine profile in endocrine
pancreas and plasma may hold great promise for more
efficient b-cell dysfunction treatment and T2DM man-
agement. Teixeira de Lemos et al. [34] demonstrated,
using the above mentioned animal model of obese
T2DM, the ZDF rat, that exercise training was able to
prevent accumulation of pro-inflammatory cytokines
(IL-6 and TNF-a) on endocrine pancreas (Figure 3). A
decrease in pancreas immunostaining of both cytokines
was observed, suggesting a protective effect of regular
physical exercise against local inflammation.
Final remarks and conclusions
The recognition that a tight glycaemic control signifi-
cantly reduces the microvascular and macrovascular
complications in T2DM indicates hyperglycaemia as the
main goal of treatment. Indeed, the reduction in HbA1c
values was shown to have a positive impact on cardio-
vascular complications associated with diabetes. Epide-
miological data from the UKPDS (United Kingdom
Prospective Diabetes Study) suggest that the reduction
of blood glucose decreases the risk of cardiovascular dis-
ease, which was supported by recent meta-analyses that
concluded by a beneficial impact of glycaemic control in
reducing events of non-fatal myocardial infarction and
events of coronary heart disease, despite no significant
effect on all-cause mortality [107,108]. Thus, neverthe-
less the key role of hyperglycaemia lowering in T2DM
management and prevention of its serious complica-
tions, the correction of other associated risk factors,
such as dyslipidaemia, hypertension, hypercoagulability,
obesity and insulin resistance, is also crucial for better
efficacy of treatment.
The current therapeutic arsenal for treatment of T2D
is mainly based on:
i) - reduce hepatic glucose production (metformin);
ii) - stimulate insulin secretion (sulfonylureas,
glinides);
iii) - delay the intestinal glucose absorption (alpha-
glucosidase inhibitors);
iv) - increase sensitivity of muscle, fat and liver to
insulin (Thiazolidinediones);
v) - suppress glucagon secretion and delay gastric
emptying [Glucagon-like peptide-1 (GLP-1)
agonists];
vi) - extend GLP-1 activity after meals in order to
reverse the failure of pancreatic beta cells [Dipeptidyl
peptidase-4 (DPP-4) Inhibitors];
vii) - stimulate peripheral glucose uptake and
decrease hepatic glucose production (insulin).
In addition, for the correction of other risk factors
encountered in T2DM patients, other drugs are also
requested:
i) - lipid lowering drugs (statins, ezetimibe, fibrates
or combinations);
ii) - antihypertensive drugs [ACE inhibitors, angio-
tensin II receptor antagonists (ARAs), beta blockers,
diuretics, calcium entry blockers];
iii) - antiplatelet drugs [acetylsalicylic acid (ASA),
clopidogel, triflusal or associations].
A recent proposal to condense into a single drug more
active principles (polypill), as a tool for primary and sec-
ondary prevention of cardiovascular disease and T2DM
evolution, is, in theory, apparently very attractive. How-
ever, apart from the putative side effects and the so
large range of possible drug-to-drug interactions, an
antidiabetic polypill will need to be adapted to one or
more stages of diabetic dysmetabolism, which is a pro-
gressive disease. The large size of formulations, as well
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as the loss of flexibility of the therapy, which is essential
for controlling metabolic changes and to handle varia-
tions in blood pressure, should be also be carefully
considered.
Throughout this document, which reviewed the bene-
ficial effects of regular exercise on the correction of risk
factors for T2DM, the similarities between the effects of
chronic exercise and a putative antidiabetic polypill
were highlighted, with the additional advantage that
exercise, when practiced regularly and under moderate
intensity (training), do not causes relevant side effects
and presents a greater metabolic effectiveness if com-
pared with an antidiabetic polypill (Figure 4).
The studies developed by our group [32-34], using an
animal model of obese T2DM, clearly demonstrated that
the practice of a regular and moderate intensity swim-
ming protocol (training), although unable to fully
reverse pancreas lesions, has prevented and/or delayed
the worsening of diabetic dysmetabolism. The obtained
results highlighted the pleiotropic effect of exercise
training, viewed by several properties, including:
i) - improvement of arterial vascular compliance and
blood pressure;
ii) - correction of dysglycaemia and dyslipidaemia;
iii) - increment of antioxidant defenses, thus pro-
moting a reduction of oxidative aggression;
iv) - decrease of pro-inflammatory profile and
increased anti-inflammatory markers;
v) - reduced pancreatic dysfunction in Langerhans
islets, responsible for the cell failure and appearance
of relative insulin deficiency with insulin resistance,
a feature of advanced stages of T2DM.
The cardiometabolic protective role of exercise train-
ing in T2DM becomes more clear when considering the
pleiotropic actions encountered by our group, which
were corroborated by other studies in animal models, as
Figure 3 Interleukin-6 (A) and TNF-a (B) immunostaining of islets of Langerhans (original magnification 400×) in ZDF rats. (A1 and B1)
- Staining of the islet of a 20-wk-old sedentary diabetic (fa/fa) rat showing high immunostaining (+++); (A2 and B2) - Staining of the islet of a
20-wk-old exercised diabetic (fa/fa) rat with a significant reduction in the expression of interleukin-6 (A) and TNF-a (B) immunoreactivity (+).IL-6,
interleukin 6; TNF-a, tumour necrosis factor a. Adapted from [34]).
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well as in humans, as above commented in detail,
together with other important action that undoubtedly
contribute to prevent or attenuate diabetes evolution
and its complications, which includes:
- accentuation of the reduced myocardial b-adrener-
gic responsiveness in diabetic rats, mainly due to the
reduction in b2-adrenoceptors expression, which
might have protective action [109];
- decreases in resting systolic blood pressure and 24-
hour proteinuria in obese diabetic patients with
chronic kidney disease (CKD), which is in favour of
reduced cardiovascular complications in these
patients [110];
- reduction in plasma endothelin 1 (ET-1) and NO
content, together with beneficial effects on anthro-
pometric measurements and plasma oxidant stress
markers, suggesting an improvement of endothelial
dysfunction in patients with IGT [111];
- improvement of TNF-a and IL-6 release impair-
ment by non-infiltrated peritoneal macrophages in a
rat model of obese metabolic syndrome [98,99].
Considering the data now reviewed, exercise prescrip-
tion might be recommended as adjuvant of drug therapy
for treatment/attenuation of T2DM and its serious com-
plications, which is in line with the recommendations of
American diabetes Association (ADA) and European
Association for the Study of Diabetes (EASD) algorithm
for the management of type 2 diabetes, further strength-
ened by a possible reduction in the dose of anti-diabetic
drugs, as well as of other drugs used to correct/attenu-
ate the associated cardiometabolic risk factors. This data
is even more relevant when recognizing that the epi-
demic of obesity and insulin resistance is already
focused on children and adolescents. However, we must
recognize that further research is needed, namely in
humans, in order to establish the preferred type, dura-
tion and intensity of training that should be practiced in
order to maximize the benefits of exercise for different
subgroups of T2DM patients.
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